Table 3 Overview of published clinical trial studies of epigenetic drugs in MM
From: Epigenetic strategies to reverse drug resistance in heterogeneous multiple myeloma
Epigenetic function | Compound | Phase | Reference |
|---|---|---|---|
BET inhibitor | OTX015/MK-8628 | I | [158] |
BET inhibitor | CPI-0610 | I | [159] |
BET inhibitor | GSK525762 | I/II | [159] |
DNMT/HDAC inhibitor | Azacitidine/phenylbutyrate | III | [159] |
HDAC inhibitor | Abexinostat | I | [159] |
HDAC inhibitor | Belinostat | II | [159] |
HDAC inhibitor | CI-994 | II | [159] |
HDAC inhibitor | CUDC-907 | I | [159] |
HDAC inhibitor | Entinostat | I | [159] |
HDAC inhibitor | ITF2357 | II | [159] |
HDAC inhibitor | Panobinostat | II | [159] |
HDAC inhibitor | Panobinostat in combination with bortezomib and dexamethasone | FDA approved | |
HDAC inhibitor | Panobinostat in combination with everolimus | I/II | [159] |
HDAC inhibitor | Rocilinostat | I/II | [159] |
HDAC inhibitor | Tefinostat | I | [159] |
HDAC inhibitor | Valproate | I | [159] |
HDAC inhibitor | Vorinostat | I/II | [159] |
HAT inhibitor | Curcumin | Preliminary clinical study | [160] |